MedPath

CellAdhesionMolecule EndometriosisRatio - CAMERA

Conditions
Identification of Biomarkers in Serum
Endometriosis (Diagnosis)
Registration Number
NCT04294017
Lead Sponsor
Heinrich Husslein
Brief Summary

Background: Endometriosis, which is characterized by the growth of endometrial stroma and glands outside of the uterine cavity, is estimated to occur in 6-10% of women of reproductive age. Clinical presentation of endometriosis can vary widely, often significantly reducing quality of life, and the mean interval between the onset of symptoms and obtaining a definitive diagnosis is approximately 10 years. Currently, laparoscopy is the gold standard for diagnosing endometriosis; however, this procedure is invasive, carries surgery-related risks, and contributes to diagnostic delay. Therefore, the field has an urgent need for an efficient, sensitive, non-invasive tool for diagnosing endometriosis.

Recently, it was shown that sVCAM-1/sICAM-1 ratio is a promising serum biomarker, which may lead to the development of a new, efficient, sensitive, non-invasive tool for diagnosing endometriosis, thereby potentially avoiding surgical interventions.

Primary aim: To determine whether the serum sVCAM-1/sICAM-1 ratio can be used todiagnose endometriosis.

Study design: Prospective multicenter validation study

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
300
Inclusion Criteria
  • unfulfilled desire for children
  • chronic pelvic pain
  • suspicion of endometriosis
  • cysts
  • myomas
Exclusion Criteria
  • acute infections
  • malign diseases
  • drug abuse
  • pregnancy
  • infectious diseases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sICAM and sVCAM in serumup to 1 week

levels of these two soluble adhesion factors in serum of patients and controls

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Medical University Vienna

🇦🇹

Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath